(VSTA) Joins HESI’s Cardiac Safety Committee and Working Groups

Industry-Led Consortium Developing a Novel Paradigm for Cardiac Safety Evaluation of New Drugs

(MEIL) Earns BQ-9000 Producer and Marketer Status

(NFLX) To Launch In Germany, Austria, Switzerland, France, Belgium And Luxembourg

World’s Leading Internet Television Network Plans Significant Expansion In Europe, Offering Entertainment Anytime, Anywhere, On Any Device For A Low Monthly Price

LOS GATOS, Calif., May 21, 2014  — Netflix, Inc. (NASDAQ: NFLX), plans to significantly expand in Europe later this year, offering a wide-range of entertainment for a low monthly price in Germany, Austria, Switzerland, France, Belgium and Luxembourg.

Upon launch, broadband users in these countries can subscribe to Netflix and instantly watch a curated selection of Hollywood, local and global TV series and movies, including critically-acclaimed Netflix original series, whenever and wherever they like on TVs, tablets, phones, game consoles and computers.

Since launching its streaming service in 2007, Netflix has put consumers in charge of when and how they enjoy their entertainment. Members can play, pause and resume watching series and films across devices, always without commercials or commitments. Using the unique Netflix recommendation engine, each member is presented a personalized list of titles to enjoy from Netflix.

Netflix is the world’s leading Internet television network with over 48 million members in more than 40 countries enjoying more than one billion hours of TV shows and movies per month. The continued European expansion follows the launch of Netflix in the UK and Ireland, Denmark, Finland, Norway, Sweden (2012) and the Netherlands (2013).

People interested in becoming Netflix members in France, Germany, Austria, Switzerland, Belgium and Luxembourg can go to www.netflix.com today and sign up to receive an e-mail alert when Netflix has launched.

Further details, including pricing, programming and supported devices will be available at a later date.

About Netflix

Netflix is the world’s leading Internet television network with over 48 million members in more than 40 countries enjoying more than one billion hours of TV shows and movies per month, including original series. For a low monthly price, Netflix members can watch as much as they want, anytime, anywhere, on nearly any Internet-connected screen. Members can play, pause and resume watching, all without commercials or commitments.

(DWCH) Announces Partnership with MDS Tech Inc.

— Adding Real-Time Data Visualisation to Big Data and Integration Portfolio

CHELMSFORD, Massachusetts and LONDON and ABU DHABI, United Arab Emirates, May 21, 2014  — Datawatch Corporation (NASDAQ-CM: DWCH), a leading global provider of visual data discovery solutions, and MDS Tech, part of the MiDiS Group and the holding company for numerous affiliates in the Middle East, Europe and Turkey, today announced a strategic regional partnership which will span Eastern Europe and the Middle East.  MDS Tech companies, which offer full systems integration and best-of-breed solutions in Data Management, Business Analytics and Mobility solutions, will now offer the full Datawatch visual data discovery solution that optimises any data – regardless of its variety, volume, or velocity – and delivers next generation analytics.

Logo – http://photos.prnewswire.com/prnh/20121015/NE92833LOGO

With a core expertise in Enterprise Information Management projects developed over 21 years, MDS Tech delivers high value business solutions to its Tier-One customers in Banking, Public Sector, Healthcare, Telecommunications and Oil and Gas across the region.

“This was a key strategic decision for MDS Tech.  In line with our vision to support a true and robust Big Data strategy that allows companies to access their valuable data assets regardless of data type, volume or velocity, we see Datawatch as a powerful addition that completes our solutions portfolio,” said Tony Achkar, vice president, MDS Tech states.  “It helps companies quickly unlock the power of their Big Data and provides data streaming, integrating multiple formats including unstructured and semi-structured data, to deliver real-time business insight.”

As part of the agreement MDS Tech will provide pre-sales, consultancy and local language support across the Middle East, Turkey & Eastern Europe. This ‘one contract’ arrangement through MDS Tech companies allows customers to purchase, implement and get full support from a single trusted local supplier.  The combined Datawatch and MDS Tech solution brings out the true value of next generation analytics and, as a measure of the commitment to this initiative, MDS Tech has set up a separate entity dedicated entirely to the sale and support of the Datawatch portfolio.  This new organisation reports into Tony Achkar, and has been established to support all MDS Tech operations across the geos.

Haj Muntz, vice president, Datawatch EMEA adds, “The volume and variety of data that organisations need to analyse is growing exponentially, just as the speed of business is driving a transformation in the way these companies service their customers. The rapid expansion of the geography covered by MDS Tech amplifies this effect and so, to be successful, a new approach to data discovery is needed.  In partnership with Datawatch, MDS Tech will be able to offer the full spectrum of innovation solutions to attain immediate business insight, spots trends, identify fraud and key business outliers to help with time-critical decision making. MDS has a reputation for quality, and in them we feel that we have found the ideal strategic partner to develop our footprint across the region.”

About Datawatch Corporation
Datawatch Corporation (NASDAQ-CM: DWCH) provides visual data discovery software that optimizes any data – regardless of its variety, volume, or velocity – delivering next generation analytics to reveal valuable insights for improving business. Its unique ability to integrate structured, unstructured, and semi-structured sources like reports, PDF files and EDI streams with real-time streaming data into visually rich analytic applications allows users to dynamically discover key factors that impact any operational aspect of their business. This ability to perform visual discovery against any data sets Datawatch apart in the big data and visualization markets. Organizations of every size, worldwide use Datawatch products, including 99 of the Fortune 100. Datawatch is headquartered in Chelmsford, Massachusetts with offices in New York, London, Munich, Stockholm, Singapore, Sydney and Manila, and with partners and customers in more than 100 countries worldwide. See the Whole Story for yourself by downloading the free trial at www.datawatch.com/trial.

ABOUT MDS Tech
MDS Tech is part of the Midis Group, a group of companies established over 40 years ago, with over 2800 Employees across 3 continents, over 120 companies and 100 TOP resellers Awards.  MDS Tech is a group of companies with an exceptional track record of providing Turnkey IT Solutions with over 20 Years of in depth experiences in helping customers Manage, Integrate, Analyse, & Mobilize Business Mission Critical Data across the enterprise.

Safe Harbour Statement under the Private Securities Litigation Reform Act of 1995
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any such statements, including but not limited to those relating to results of operations, contained herein are based on current expectations, but are subject to a number of risks and uncertainties that may cause actual results to differ materially from expectations. The factors that could cause actual future results to differ materially from current expectations include the following: risks associated with the continuing weak global economy; risks associated with fluctuations in quarterly operating results due, among other factors, to the size and timing of large customer orders; risks associated with acquisitions, including the recent acquisition of intellectual property from Math Strategies and the acquisition of Panopticon; the volatility of Datawatch’s stock price; limitations on the effectiveness of internal controls; rapid technological change; Datawatch’s dependence on the introduction of new products and possible delays in those introductions; competition in the software industry generally, and in the markets for next generation analytics in particular; Datawatch’s dependence on its principal products, proprietary software technology and software licensed from third parties; risks associated with international sales and operations; risks associated with indirect distribution channels and co-marketing arrangements, many of which were only recently established; the adequacy of Datawatch’s sales returns reserve; risks associated with a subscription sales model; Datawatch’s dependence on its ability to hire and retain skilled personnel; disruption or failure of Datawatch’s technology systems that may result from a natural disaster, cyber-attack or other catastrophic event; and uncertainty and additional costs that may result from evolving regulation of corporate governance and public disclosure. Further information on factors that could cause actual results to differ from those anticipated is detailed in various publicly-available documents, which include, but are not limited to, filings made by Datawatch from time to time with the Securities and Exchange Commission, including but not limited to, those appearing in the Company’s Annual Report on Form 10-K for the year ended September 30, 2013 and Form 10-Q for the quarter ended December 31, 2013. Any forward-looking statements should be considered in light of those factors.

Investor Contact:
Datawatch Investor Relations
investor@datawatch.com
Phone: +1-978-441-2200 ext. 8323

Media Contact:
Sarah Bernardi
Datawatch Corporation
Sarah_Bernardi@datawatch.com
Phone: +1-978-441-2200 ext. 8387
Twitter: @datawatch

(WIFI) Atlanta Hawks, Philips Arena Partner with Boingo for Next Gen Wireless Networks

Boingo’s Cellular Distributed Antenna System and Wi-Fi Networks to Enhance Fan Experience at the Southeast’s Premier Sports and Entertainment Venue

Boingo Wireless (NASDAQ: WIFI), the leading DAS and Wi-Fi provider that serves consumers, carriers and advertisers worldwide, and Philips Arena, one of the top concert and event venues in North America and home of the NBA’s Atlanta Hawks, today announced an exclusive wireless network partnership.

Boingo will design, install and manage neutral host cellular Distributed Antenna System (DAS) and Wi-Fi networks at the Arena for fan use, leveraging the latest in wireless technology. The networks are slated to launch prior to the next NBA season.

The Boingo wireless networks will provide comprehensive coverage for fans throughout the Arena, which is home to the Hawks as well as the WNBA’s Atlanta Dream, and hosts more than 160 additional sports and entertainment events each year. The cellular Distributed Antenna System network will provide enhanced data capacity for spectators in all areas of the arena, as well as coverage for Arena operations staff. Boingo’s approach to neutral host DAS networks enables maximum wireless carrier participation, ensuring that more fans can access the network.

Boingo will also launch a Wi-Fi network for fan use, providing fast connectivity throughout the Arena seating areas, concessions and concourse areas. Wi-Fi network access will be provided free to fans, supported by sponsors and advertisers. Boingo Media, Boingo’s advertising and sponsorship services group, will collaborate closely with Philips Arena on wireless sales.

“We have continually stated our goal to reimagine Philips arena and enhance our fan experience to create the best event atmosphere in the nation for our members and partners. Our partnership with Boingo will greatly aid us in both areas as we look to incorporate technology to an even greater degree and keep all of our guests connected,” said Andrew Steinberg, EVP and Chief Revenue Officer of the Atlanta Hawks and Philips Arena. “Boingo is a leader in major league and university stadium and arena wireless network management with strong wireless carrier relationships, and proven success in building networks that can meet the demands of today’s fans. We are looking forward to working with Boingo to deliver blazing fast connectivity for our spectators and staff.”

“It’s an honor to partner with Philips Arena, one of the most celebrated event venues in North America. Our next generation wireless networks will deliver an exceptional connectivity experience, enhancing the Arena’s already stellar reputation and amenities,” said Nick Hulse, president of Boingo Wireless. “Our cellular DAS and Wi-Fi networks will be built to scale with the projected future increases in consumer connectivity, and to enable future location based services and technology applications in venue to keep it at the top of the ‘best venues’ lists for years to come.”

Philips Arena was named one of the top 5 venues in the country by Pollstar Magazine, based on ticket sales of more than 500,000 in 2013. The Arena has received this honor for seven out of the last eight years, a record rivaled only by Madison Square Garden. The Arena has capacity for more than 20,000 fans, and hosts events including games, concerts and family entertainment more than 300 days a year.

Boingo Wireless is a leading provider of small cell and Wi-Fi networks at major league stadium and university venues, including Chicago’s Soldier Field, University of Arizona’s Arizona Stadium, and the EnergySolutions Arena, home of the NBA’s Utah Jazz. Boingo is also the leading provider of Wi-Fi in airports worldwide, with service in more than 75 airports around the globe and nearly 60% of the U.S.’s top 50 airports, including Chicago O’Hare, New York’s John F. Kennedy and Los Angeles International Airport. Boingo is also the leading provider of Distributed Antenna System networks in U.S. airports.

About Boingo Wireless

Boingo Wireless, Inc. (NASDAQ: WIFI) helps the world stay connected. Our vast footprint of small cell networks cover more than a million DAS and Wi-Fi locations and reaches more than 1 billion consumers annually – in places as varied as airports, stadiums, universities, and military bases. For more information about the Boingo story, visit www.boingo.com.

About the Atlanta Hawks and Philips Arena

The Atlanta Hawks, a member of the National Basketball Association since 1968, strive to be champions on the court and in the community and to create lifelong memories along the way. On the court, the Hawks have reached the playoffs in seven consecutive seasons, which is the longest streak in the Eastern Conference. Off the court, the Hawks have awarded millions in charitable and in-kind contributions since 2004, including grants to area non-profits, scholarships for high school students and renovation of basketball courts in underserved neighborhoods. Philips Arena is consistently ranked among the top 10 concerts and event venues in the world. In April 2009, Philips Arena became the first NBA arena to achieve LEED certification for an existing building as specified by the United States Green Building Council (USGBC). For more information on the Hawks, log on to www.hawks.com today or follow us on twitter @ATLHawks.

Boingo, Boingo Wireless, the Boingo Wireless Logo and Don’t Just Go. Boingo are registered trademarks of Boingo Wireless, Inc. All other trademarks are the properties of their respective owners.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that involves risks, uncertainties and assumptions. Forward-looking statements can be identified by words such as “anticipates,” “intends,” “plans,” “seeks” “believes,” “estimates,” “expects” and similar references to future periods. These forward-looking statements include the quotations from management in this press release, as well as any statements regarding Boingo’s strategic plans and future guidance. Forward-looking statements are based on the company’s current expectations and assumptions regarding its business, the economy and other future conditions. Since forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The company’s actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, as well as other risk and uncertainties described more fully in documents filed with or furnished to the Securities and Exchange Commission (“SEC”), including Boingo’s Form 10-K for the year ended December 31, 2013 filed with the SEC on March 17, 2014, and Form 10-Q for the quarter ended March 31, 2014 filed with the SEC on May 12, 2014. Any forward-looking statement made by Boingo in this press release speaks only as of the date on which it is made. Factors or events that could cause the company’s actual results to differ may emerge from time to time, and it is not possible for Boingo to predict all of them. Boingo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

(ERB) Receives 510(K) Clearance for the XL200 Clinical Chemistry Analyzer

ERBA Diagnostics, Inc. (NYSE MKT: ERB), a fully integrated in vitro diagnostics company, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) on the 510(k) premarket submission that ERBA Diagnostics had filed for its new clinical chemistry analyzer – the XL 200.

The XL-200 is a state-of-the-art, random access, clinical chemistry analyzer that can perform up to 400 tests per hour. Clinical chemistry analysis is one of the most widely and routinely performed diagnostics procedures in all clinical diagnostics laboratories.

Sanjiv Suri, Interim Chief Executive Officer of ERBA Diagnostics, said, “We are excited with this clearance as it enables us to provide a comprehensive clinical chemistry system with instrument and reagent kits for routine clinical chemistry and electrolytes. We expect the XL 200 to complement and enhance the existing portfolio of immunology and hematology systems we offer to U.S. hospitals, reference labs and physician office labs. We also expect the XL 200 to enhance our position with our key distributors to leverage their efforts and become more relevant to their customers with the enhanced offering.”

Mr. Suri continued, “Industry analysts estimate that the size of the U.S. clinical chemistry market is approximately $5.0 billion. We expect the XL 200 to give us an entry in to this significant market and contribute to our revenue growth in future. Industry analysts have stated that they expect a rise in the number of insured in the U.S. will likely be compounded with other factors to revive the IVD market.”

About ERBA Diagnostics, Inc.

ERBA Diagnostics, Inc. (www.erbadiagnostics.com), headquartered in Miami Lakes, Florida, is a fully integrated in vitro diagnostics company that develops, manufactures and distributes in the United States and internationally, proprietary diagnostic reagents, test kits and instrumentation, primarily for autoimmune and infectious diseases, clinical chemistry, hematology and diabetes through its six subsidiaries – Diamedix Corporation (U.S.), Delta Biologicals S.r.l. (Europe), ImmunoVision, Inc. (U.S.), Drew Scientific, Inc. (U.S.), JAS Diagnostics, Inc. (U.S.), and Erba Diagnostics Mexico S.A. (Latin America).

Safe Harbor Statement

Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect the business and prospects of ERBA Diagnostics, Inc., including, without limitation, the risks and uncertainties related to: the ability of ERBA Diagnostics to commercially launch the XL 200 when expected, or at all; the impact of the anticipated timing of the commercial launch of the XL 200 on the judgments and estimates ERBA Diagnostics has made with respect to its financial condition, operating results and cash flows; ERBA Diagnostics’ ability to successfully market the XL 200; the ability of the XL 200 to perform as expected; the ability of the XL 200 to complement and enhance ERBA Diagnostics’ existing portfolio of instruments and reagent kits; the ability of the XL 200 to enhance ERBA Diagnostics’ position with its key distributors, whether by enabling them to leverage their efforts and become more relevant to their customers with enhanced offerings, or otherwise; the ability of the XL 200 to be a source of revenue growth for ERBA Diagnostics in the future; constantly changing, and ERBA Diagnostics’ compliance with, governmental regulation; ERBA Diagnostics’ ability to achieve cost advantages from its own manufacture of instrument systems, reagents and test kits; and economic, competitive, political, governmental and other factors affecting ERBA Diagnostics and its operations, markets and products. In addition to the risks and uncertainties set forth above, investors should consider the economic, competitive, governmental, technological and other risks and uncertainties discussed in ERBA Diagnostics’ filings with the Securities and Exchange Commission, including, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in such filings.

(EZPW) Names William C. Love Non-Executive Chairman

AUSTIN, Texas, May 21, 2014  — EZCORP, Inc. (Nasdaq:EZPW), a leading provider of easy cash solutions for consumers, today announced that its Board of Directors has elected William C. Love to the position of non-executive Chairman of the Board effective May 19, 2014. The company also announced that it has notified Madison Park, LLC that its current Advisory Services Agreement will terminate effective June 19, 2014.

Board Selects Non-Executive Chairman

After a thorough review and analysis of board structure and other corporate governance matters by its Governance Committee, the Board of Directors determined that an independent, non-executive Chairman of the Board was the best choice for the company at this stage of its growth and elected Mr. Love to the position. The board also decided to make the Governance Committee, consisting of independent directors, a permanent board committee. The company now has three permanent independent committees including Compensation and Audit.

Mr. Love has served as an independent director of EZCORP since October 2008 and has been serving as Lead Director since September 2013. He also serves as chair of the board’s Audit Committee.

“I look forward to working with Bill as I hand off the responsibilities of the Chairman’s role,” said Sterling Brinkley, EZCORP’s outgoing Executive Chairman. “Bill has provided EZCORP with valuable advice and counsel, thoughtful strategic guidance and an unwavering commitment to compliance, integrity and transparency. I have every confidence that he will continue serve the company and its shareholders well in his new role.”

Paul Rothamel, EZCORP’s President and Chief Executive Officer, added, “I’d like to thank the independent directors for their careful and thoughtful work, and I want to personally congratulate Bill Love on his election as our first non-executive Chairman of the Board. I look forward to working with Bill and the rest of the board and the senior management team to continue to deliver superior service to our customers and continue to pursue superior long-term value for our shareholders.”

Madison Park Agreement to Terminate

The company also announced that it will terminate its advisory services arrangement with Madison Park, LLC. Madison Park, a business and financial advisory firm wholly owned by Phillip E. Cohen, the beneficial owner of all of the company’s outstanding Class B Voting Common Stock, was engaged to provide advisory services related to EZCORP’s business and long term strategic plan through September 2014. The company yesterday delivered a 30-day termination notice to Madison Park, as permitted by the terms of the agreement.

In reaching the decision to terminate the advisory services arrangement with Madison Park, both management and the Board considered the valuable advice and counsel Madison Park has provided, but concluded that, in light of the company’s current strategic plan as well as its existing capabilities, the Madison Park services are no longer needed.

About EZCORP

EZCORP, Inc. is a leader in delivering easy cash solutions to our customers across channels, products, services and markets. With approximately 7,500 team members and approximately 1,400 locations and branches, we give our customers multiple ways to access instant cash, including pawn loans and consumer loans in the United States, Mexico, Canada and the United Kingdom. We offer these products through four primary channels: in-store, online, at the worksite and through our mobile platform. At our pawn and buy/sell stores and online, we also sell merchandise, primarily collateral forfeited from pawn lending operations and used merchandise purchased from customers.

EZCORP owns controlling interests in Prestaciones Finmart, S.A.P.I. de C.V., SOFOM, E.N.R. (doing business under the names “Crediamigo” and “Adex”), a leading provider of payroll deduction loans in Mexico; and in Renueva Commercial, S.A.P.I. de C.V., an operator of buy/sell stores in Mexico under the name “TUYO.” The company also has a significant investment in Cash Converters International Limited (CCV.ASX), which franchises and operates a worldwide network of over 700 stores that provide personal financial services and sell pre-owned merchandise.

For the latest information on EZCORP, please visit our website at: http://investors.ezcorp.com/.

Forward-Looking Statements

This announcement may contain certain forward-looking statements regarding the company’s expected operating and financial performance for future periods. These statements are based on the company’s current expectations. Actual results for future periods may differ materially from those expressed or implied by these forward-looking statements due to a number of uncertainties and other factors, including fluctuations in gold prices or the desire of our customers to pawn or sell their gold items, changes in the regulatory environment, changing market conditions in the overall economy and the industry, and consumer demand for the company’s services and merchandise. For a discussion of these and other factors affecting the company’s business and prospects, see the company’s annual, quarterly and other reports filed with the Securities and Exchange Commission.

CONTACT: Mark Trinske
         Vice President, Investor Relations and Communications
         EZCORP, Inc.
         (512) 314-2220
         Investor_Relations@ezcorp.com
         http://investors.ezcorp.com/

(MEIL) Announces Pricing of Public Offering of Common Stock

(OVRL) NovaGlass Success Leads to Glassware 2.0 and V3 Appliance Demand

Hundreds of Attendees Test Drive V3 Appliances and Glassware 2.0 Virtualization Software on SnapServer DX2 Appliances at Launch

(INSM) Positive Open Label Data from Phase 2 Clinical Trial of ARIKAYCE

Insmed Incorporated (Nasdaq:INSM) today announced additional results from the Company’s phase 2 clinical trial of ARIKAYCE^TM, or liposomal amikacin for inhalation, for the treatment of patients with treatment resistant nontuberculous mycobacterial (NTM) lung infections. The results are highlighted in a poster entitled, “A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation (ARIKAYCE) in Patients with Recalcitrant Nontuberculous Mycobacterial Lung Disease,” that will be presented today at the American Thoracic Society’s Annual Meeting 2014 in San Diego, California by Kenneth N. Olivier, M.D., M.Ph., National Institute of Allergy and Infectious Diseases and a co-Principal Investigator of the study. The poster is available on the Company’s website at www.insmed.com.

At the conclusion of the 84-day double blind phase of the trial, 78 of the 80 patients agreed to receive once-daily ARIKAYCE plus standard of care treatment for an additional 84 days. Data from 68 of these patients who completed the visits during the additional open label phase were available for inclusion in the poster. These results collected from the open label phase show that 21 of these patients were culture negative for NTM at Day 168. This data reflects 10 patients who were culture negative at Day 84 as well as 5 additional patients from the ARIKAYCE arm and 6 additional patients who were on placebo, switching to ARIKAYCE during the open-label phase. The number of patients with negative cultures increased from the double blind phase of the trial in which 11 out of 44 patients treated with ARIKAYCE (added to standard of care treatment) demonstrated negative cultures by day 84 of the study as compared to 3 out of 45 patients treated with standard of care plus placebo.

“We are encouraged by these additional and durable culture conversions which we believe is the ultimate goal in the treatment of NTM lung infections,” said Will Lewis, President and Chief Executive Officer of Insmed. “The patients screened for admission to this trial are recalcitrant to treatment. While the entry criteria for this trial required a minimum of 6 months on standard of care therapy, over 75% of patients entering this trial were treated with standard of care therapy for more than a year, yet remained culture positive. In addition, a majority of these patients suffer from at least one additional pulmonary co-morbidity, such as bronchiectasis or cystic fibrosis, making the hurdle quite high for showing any improvement and making these results that much more encouraging for patients suffering from this disease. We now look forward to the regulatory discussions in the United States and Europe that will guide our path forward.”

In the next several months, the Company plans to incorporate the trial results into discussions with the regulatory agencies in the United States and Europe to determine next steps for ARIKAYCE in the treatment of NTM lung infections. Based upon the culture conversion results, in April 2014 the Company applied for Breakthrough Therapy Designation for ARIKAYCE in the United States. ARIKAYCE has already received Orphan Drug, Qualified Infectious Disease Product (QIDP) and Fast Track designations from the U.S. Food and Drug Administration (FDA) for the treatment of NTM lung infections and recently received Orphan Drug Designation from the European Medicines Agency (EMA).

Clinical Trial Design and Key Endpoints

The randomized, double-blind, placebo-controlled phase 2 clinical trial compared ARIKAYCE (590 mg delivered once daily for 84 days), added to standard of care treatment, versus standard of care treatment plus placebo, in 89 adult patients with treatment resistant NTM lung disease at 19 sites in North America. Eligibility for the study required patients to have been on the American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines-based therapy for at least six months prior to screening with persistently positive mycobacterial cultures. Following the randomized portion of the study, all eligible patients had the option to receive ARIKAYCE once daily for an additional 84 days in an open-label design.

The primary efficacy endpoint of the study was a semi-quantitative measurement of the change in mycobacterial density on a seven-point scale from baseline (Day 1) to the end of the randomized portion of the trial (Day 84). ARIKAYCE did not meet the pre-specified level for statistical significance although there was a positive trend (p=0.148) in favor of ARIKAYCE. The key secondary endpoint of culture conversion reached statistical significance in favor of ARIKAYCE.

Safety

Patients receiving ARIKAYCE experienced adverse events consistent with those seen in similar patient populations receiving inhaled antibiotics. Overall, mild to moderate upper respiratory irritation was more common in the ARIKAYCE arm compared to the placebo arm and there was no difference in severe serious adverse reactions or hemoptysis between the two arms. There was one Suspected Unexpected Serious Adverse Reaction (SUSAR) observed in the double-blind phase and one SUSAR observed in the open-label phase. Instances of hearing loss or tinnitus, a side effect more commonly associated with intravenous dosing of amikacin, were evenly balanced between the ARIKAYCE and placebo arms.

About Nontuberculous Mycobacteria (NTM)

Nontuberculous mycobacteria (NTM) are organisms found in the soil and water that can cause serious lung disease in susceptible individuals, for which there are currently limited effective treatments and no approved therapies. The prevalence of NTM disease is reported to be increasing, and according to reports from the American Thoracic Society is believed to be greater than that of tuberculosis in the U.S. According to the National Center for Biotechnology Information, epidemiological studies show that presence of NTM infection is increasing in developing countries, perhaps because of the implementation of tap water. Women with characteristic phenotype are believed to be at higher risk of acquiring NTM infection along with patients with defects on cystic fibrosis transmembrane conductance regulators.

NTM lung disease is often a chronic condition that can lead to progressive inflammation and lung damage, and is characterized by bronchiectasis and cavitary disease. NTM infections often require lengthy hospital stays for medical management. Treatment usually involves multi-drug regimens that can be poorly tolerated and have limited effectiveness, especially in patients with severe disease or in those who have failed prior treatment attempts. According to a company-sponsored patient chart study conducted by Clarity Pharma Research, approximately 50,000 patients suffering from NTM lung disease visited physician offices in the U.S. during 2011.

About ARIKAYCE™

ARIKAYCE is a form of the antibiotic amikacin, which is enclosed in nanocapsules of lipid called liposomes. This advanced pulmonary liposome technology prolongs the release of amikacin in the lungs while minimizing systemic exposure. The treatment uses biocompatible lipids endogenous to the lung that are formulated into small (0.3 micron), charge-neutral liposomes. ARIKAYCE is administered once-daily using an optimized, investigational eFlow® Nebulizer System manufactured by PARI Pharma GmbH, a novel, highly efficient and portable aerosol delivery system.

This is the first controlled clinical trial of an antibiotic in patients suffering from NTM lung infections. There are no drugs approved by the FDA for the treatment of this chronic, debilitating disease.

About eFlow^® Technology and PARI Pharma

ARIKAYCE is delivered by an investigational eFlow^® Nebulizer System developed by PARI Pharma and optimized specifically for ARIKAYCE. The optimized device uses eFlow Technology to enable highly efficient aerosolization of medication including liposomal formulations via a vibrating, perforated membrane that includes thousands of laser-drilled holes. Compared with other nebulization technologies, eFlow Technology produces aerosols with a very high density of active drug, a precisely defined droplet size and a high proportion of respirable droplets delivered in the shortest possible period of time. eFlow Technology is not an ultrasonic nebulizer technology and is not a general purpose electronic aerosol generator nebulizer technology. Combined with its quiet mode of operation, small size, light weight and battery use, eFlow Technology reduces the burden of taking daily, inhaled treatments.

About Insmed

Insmed Incorporated is a biopharmaceutical company dedicated to improving the lives of patients battling serious lung diseases. Insmed is focused on the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. For more information, please visit http://www.insmed.com.

Forward-looking Statements

This release contains forward-looking statements. Words, and variations of words, such as “intend,” “expect,” “will,” “anticipate,” “believe,” “continue,” “propose” and similar expressions are intended to identify forward-looking statements. Investors are cautioned that such statements in this release, including statements relating to the status, results and timing of clinical trials and clinical data, the anticipated benefits of Insmed’s products, the anticipated timing of regulatory submissions, and the ability to obtain required regulatory approvals, bring products to market and successfully commercialize products constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, without limitation, failure or delay of European, Canadian, U.S. Food and Drug Administration and other regulatory reviews and approvals, competitive developments affecting the Company’s product candidates, delays in product development or clinical trials or other studies, patent disputes and other intellectual property developments relating to the Company’s product candidates, unexpected regulatory actions, delays or requests, the failure of clinical trials or other studies or results of clinical trials or other studies that do not meet expectations, the fact that subsequent analyses of clinical trial or study data may lead to different (including less favorable) interpretations of trial or study results or may identify important implications of a trial or study that are not reflected in Company’s prior disclosures, and the fact that trial or study results or subsequent analyses may be subject to differing interpretations by regulatory agencies, the inability to successfully develop the Company’s product candidates or receive necessary regulatory approvals, the ability to obtain Breakthrough Therapy Designation for ARIKAYCE in the U.S., the inability to make product candidates commercially successful, changes in anticipated expenses, changes in the Company’s financing requirements or ability to raise additional capital, and other risks and challenges detailed in the Company’s filings with the U.S. Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2013 and its subsequent quarterly reports on Form 10-Q. Investors are cautioned not to place undue reliance on any forward-looking statements that speak only as of the date of this news release. The Company undertakes no obligation to update these forward-looking statements to reflect events or circumstances or changes in its expectations.

(DNDN) Treatment with PROVENGE® Induces Antigen Spread In Prostate Cancer

May 20, 2014-Dendreon Corporation (NASDAQ: DNDN) today announced the presentation of data from the ProACT and IMPACT studies suggesting that PROVENGE^® (sipuleucel-T) elicits an immune response associated with an overall survival benefit. Also being presented are data from the PROCEED registry suggesting similar treatment patterns for urologists and oncologists in PROVENGE-treated patients with metastatic castration-resistant prostate cancer (mCRPC). The ProACT and IMPACT data will be reported in a podium presentation and the PROCEED data will be included in a general poster session during the 2014 American Urological Association (AUA) Annual Meeting from May 16-21, 2014 in Orlando, Florida.

“These data further elucidate the mechanism of PROVENGE in the treatment of mCRPC and the important role immunotherapy plays in the prescribing practices of urologists and oncologists, which may improve outcomes for patients,” said Andrew S. Sandler, M.D., executive vice president and chief medical officer at Dendreon. “The elevated immune response against prostate-specific antigen (PSA) in the ProACT and IMPACT studies is correlated with overall survival, and may point to a useful biomarker of treatment benefit.”

Clinical presentations featuring PROVENGE studies at the annual scientific urology meeting include:

• Abstract PD27-04: Simon Hall, M.D., associate professor of urology at Mt. Sinai Hospital, will present “Sipuleucel-T-Induced Antigen Spread: Immune Response to Prostate-Specific Antigen Correlates with Improved Overall Survival:” Data from the Phase III IMPACT and Phase II ProACT studies show evidence that antigen spread may occur after PROVENGE treatment, indicating the immune response evolves over time to target multiple prostate antigens. These data may help identify biomarkers of clinical outcome after treatment with PROVENGE.
  May 20,8:00 AM – 10:00 AM ET, Prostate Cancer: Advanced I (Podium Presentation, Room W304E)

• Abstract MP70-20: Matthew R. Cooperberg, M.D., M.P.H, associate professor of urology at University of California, San Francisco, will present a poster titled “Treatment Practice Patterns in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Prior to Receiving Sipuleucel-T: Data from PROCEED:” A subgroup analysis from the ongoing Phase IV registry of mCRPC patients suggest treatment patterns between urologists and oncologists are similar, helping to better understand prescribing trends prior to and following use of PROVENGE.
  May 20,10:30 AM – 12:30 PM ET, Prostate Cancer: Advanced II (Moderated Poster Session, Room W307)

“The evolution of immunotherapy treatment continues to be a focus for the future of urology research, as evidenced in the PROVENGE data presented at AUA,” said Simon Hall. M.D., associate professor of urology at Mt. Sinai Hospital. “The biomarker potential of the anti-PSA immune response suggested in the IMPACT and ProACT data is exciting as it continues to reinforce the positive impact immunotherapies and PROVENGE may have on patients with mCRPC.”

Important Safety Information for PROVENGE

PROVENGE^® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.

The safety evaluation of PROVENGE was based on 601 prostate cancer patients in four randomized clinical trials who underwent at least one leukapheresis. The most common adverse events (incidence greater-than or equal to 15%) are chills, fatigue, fever, back pain, nausea, joint ache, and headache. Serious adverse events reported in the PROVENGE group include acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events. In controlled clinical trials, severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group. Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.

To fulfill a post marketing requirement and as a part of the company’s ongoing commitment to patients, Dendreon will conduct a registry of approximately 1,500 patients to further evaluate a small potential safety signal of cerebrovascular events. In four randomized clinical trials of PROVENGE in prostate cancer patients, cerebrovascular events were observed in 3.5% of patients in the PROVENGE group compared with 2.6% of patients in the control group.

For more information on PROVENGE, please see the full prescribing information at http://www.provenge.com or call 1-877-336-3736.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon’s first product, PROVENGE^® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington, and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.

Statements in this press release that are not strictly historical in nature constitute “forward-looking statements.” Such statements include, but are not limited to, statements regarding the expected benefits of the recent and prior restructurings, the timing and elements of the restructurings, the timing and form of related charges, the expected annual operating expense reductions, expectations and beliefs regarding Dendreon’s financial position, profitability and Dendreon’s ability to break even and achieve improved performance as a result of the restructurings, statements regarding sequencing studies, statements regarding studies to advance understanding of immunotherapy and the treatment of advanced prostate cancer, statements regarding biomarkers, expectations about automation or the early detection study, expectations about advancing our pipeline, expectations regarding reductions of cost of goods sold, expectations regarding reimbursement approvals of PROVENGE® in Europe or Dendreon’s ability to launch and commercialize PROVENGE in Europe, expectations regarding the presentation of clinical data, developments affecting Dendreon’s U.S. and global business and prospects, beliefs and expectations regarding potential revenue and earnings from product sales, including beliefs regarding Dendreon’s ability to grow sales, expectations regarding market size, target market, and market opportunity, beliefs regarding the impact of our direct to consumer advertising, expectations with respect to our sales force execution and effectiveness, progress generally on commercialization efforts for PROVENGE, and expectations about clinical trial enrollments. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause Dendreon’s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, our inability to achieve and sustain commercial success for PROVENGE; the identification of efficacy, safety or other issues with PROVENGE; a slower than anticipated adoption by treating physicians of PROVENGE for the treatment of patients with advanced prostate cancer for a variety of reasons, including competing therapies, instability in our sales force, the risk that we cannot replace vacant sales positions on a prompt basis, perceived difficulties in the treatment process, delays in obtaining reimbursement or for other reasons; any promotional limitations imposed by the FDA or the EU on our ability to commercialize and market PROVENGE; unexpected difficulties and costs associated with the rapid expansion of our commercial operations to support the commercial launch of PROVENGE; the impact of competing therapies on sales of PROVENGE, the failure to achieve reimbursement approvals in Europe, manufacturing or quality difficulties, the dilution or other effects resulting from capital raising or debt restructuring transactions, disruptions or delays and other factors discussed in the “Risk Factors” section of Dendreon’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014. All forward-looking statements are qualified in their entirety by this cautionary statement. Dendreon is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

(STML) Presentation of SL-401 Preclinical Efficacy Data in Multiple Myeloma

NEW YORK, May 20, 2014  — Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that data demonstrating SL-401 efficacy in multiple myeloma (MM) preclinical models will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30-June 3, 2014 in Chicago, IL.

In collaboration with Stemline, experiments conducted at the Dana-Farber Cancer Institute, Boston, MA, by Drs. Dharminder Chauhan and Kenneth Anderson and their MM research team demonstrated that Stemline’s clinical candidate SL-401 significantly decreased the viability of malignant cells by targeting neighboring plasmacytoid dendritic cells (pDCs) in the tumor microenvironment of the bone marrow. The researchers have previously shown that pDCs, which express the IL-3R, the target of Stemline’s SL-401, promote MM growth, potentially via IL-3/IL-3R signaling. SL-401’s novel activity against MM occurs at extremely low (picomolar) concentrations that are readily achievable in patients. Based on these results and prior data, SL-401 appears to have both direct (anti-MM) and indirect (anti-pDC) activity in this disease.

The Dana-Farber researchers also demonstrated that SL-401 was active against MM cells obtained from patients resistant to standard agents used to treat MM including bortezomib (Velcade®), dexamethasone, and lenalidomide (Revlimid®). Additionally, SL-401 demonstrated synergistic activity against MM cells when combined with bortezomib, melphalan, lenalidomide, or pomalidomide (Pomalyst®). Finally, SL-401 was also found to inhibit the formation of osteoclasts, which are the bone marrow cells responsible for bone loss, fractures, and significant morbidity in MM patients. SL-401 also stabilized the formation of bone-strengthening bone marrow cells called osteoblasts.

Eric K. Rowinsky, M.D., Chief Medical Officer and Head of Research and Development at Stemline Therapeutics, noted, “Although many agents for multiple myeloma have emerged over the last decade, these therapies ultimately fail. In such situations, new agents with unique mechanisms of action, like SL-401, have provided additional improvement in patient outcomes.” He added, “We look forward to building on these extraordinary results with SL-401 in MM which will serve as a foundation for its clinical development in this malignancy.”

About SL-401

SL-401 is a novel targeted therapy directed to the interleukin-3 receptor (IL-3R), a target present on tumor bulk and cancer stem cells (CSCs) of multiple hematologic cancer indications. SL-401 has demonstrated clinical activity in several indications, including blastic plasmacytoid dendritic cell neoplasm (BPDCN), acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS), as well as preclinical activity in multiple myeloma (MM), chronic myeloid leukemia (CML), rare IL-3R+ cancers such as chronic eosinophilic leukemia, and certain lymphoid leukemias and lymphomas.

Details on the presentation are as follows:

Effect of a novel agent SL-401, targeting Interleukin-3 Receptor (IL-3R) on plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and osteolytic bone disease
Lead Author: Dharminder Chauhan, Ph.D., Dana-Farber Cancer Institute
Authors: Dharminder Chauhan, Arghya Ray, Deepika Das Sharma, Vincent Macri, Christopher Brooks, Paul Richardson, Eric Rowinsky, and Kenneth C. Anderson
Abstract: #8599
Date and Time: Monday, June 2, 2014 – 1:15 to 5:00 PM CT
Location: S Hall A2
Poster Board: #286

A copy of the above referenced abstracts can be viewed online through the ASCO website at www.asco.org.

About Stemline Therapeutics

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk in a variety of cancer types. Stemline is currently developing two clinical-stage product candidates, SL-401 and SL-701. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R). SL-401 has demonstrated single-agent activity, including durable complete responses (CRs), in a Phase 1/2 trial in several indications including blastic plasmacytoid dendritic cell neoplasm (BPDCN) and relapsed or refractory acute myeloid leukemia (AML). SL-401 is being advanced into programs in BPDCN and other rare IL-3R+ malignancies, as well as additional hematologic cancers including AML and myeloma. SL-701 is an enhanced immunotherapy that activates the immune system to attack tumors. An earlier version of this therapy demonstrated single-agent activity, including durable CRs and partial responses (PRs), in Phase 1/2 trials in advanced adult and pediatric brain cancers. SL-701 is being advanced into trials of adults with glioblastoma multiforme (GBM) at first recurrence, and children with non-brainstem and brainstem glioma. For more information about Stemline Therapeutics, visit www.stemline.com.

Forward-Looking Statements

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially are identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

CONTACT: Investor Relations
         Stemline Therapeutics, Inc.
         750 Lexington Avenue
         Eleventh Floor
         New York, NY  10022
         Tel: 646-502-2307
         Email: investorrelations@stemline.com

(LIQD) Announces Closing of Its Public Offering of Common Stock

NEW YORK, May 20, 2014  — Liquid Holdings Group, Inc. (Nasdaq:LIQD), a provider of a single real-time platform that integrates order, execution, and risk management with reporting and shadow NAV in the cloud for the financial services community, today announced the closing of its previously announced underwritten public offering of $40,000,000 of its common stock. The public offering price was $1.25 per share and total net proceeds to the company from the public offering are expected to be approximately $36.0 million, after deducting the underwriting discount and estimated offering expenses payable by Liquid.

Liquid intends to use the net proceeds from this public offering for repayment in full of $1 million borrowed under an available line of credit and the remainder for investments in its technology and sales and marketing functions and for working capital and general corporate purposes, which may include acquisitions of complementary businesses, products or technologies.

JMP Securities LLC acted as bookrunning manager for the offering and Craig-Hallum Capital Group LLC and Sandler O’Neill + Partners, L.P. acted as co-managers.

This offering was made pursuant to an effective registration statement filed with the U.S. Securities and Exchange Commission (the “SEC”). A final prospectus describing the terms of the offering has been filed with the SEC. Copies of the final prospectus relating to this offering may be obtained by contacting JMP Securities LLC at 600 Montgomery Street, Suite 1100, San Francisco, CA 94111 or by email at ccornell@jmpsecurities.com or by phone at (415) 835-8985.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any offer or sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction. Any offer, if at all, will be made only by means of the prospectus forming a part of the effective registration statement.

About Liquid Holdings Group

Liquid Holdings Group, Inc. (Nasdaq:LIQD) is a cloud-based technology and managed services provider to the global hedge fund and active trading markets. Liquid’s solutions are delivered efficiently and securely through the cloud in a SaaS model. The Liquid platform was purpose built to manage the entire trade lifecycle by seamlessly integrating multi-currency, multi-asset trade order management and execution with real-time risk, portfolio management and shadow account reporting through a single solution. The company offers the Liquid platform or any of its components on a subscription basis to hedge fund managers, asset managers, family offices and financial institutions worldwide. Headquartered in New York City, Liquid Holdings Group was formed in 2012. For more information, please visit www.liquidholdings.com.

This press release contains forward-looking statements, including statements relating to Liquid’s expectations regarding the use of proceeds of the offering. These statements are subject to significant risks and uncertainties. Actual results could differ materially from those projected and Liquid cautions investors not to place undue reliance on the forward-looking statements contained in this release. These risks and uncertainties include, without limitation, risks and uncertainties related to the amount of net proceeds to the company from the offering and future capital needs. Risks and uncertainties relating to Liquid and this offering can be found in the “Risk Factors” section of the final prospectus for this offering filed with the SEC. Liquid undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in Liquid’s expectations.

LIQD-F

CONTACT: Contact for Investor Relations:
         Monica Gould,
         The Blueshirt Group
         +1 212 871-3927
         monica@blueshirtgroup.com

         Contact for Media Relations
         Kim Hughes,
         The Blueshirt Group
         +1 415 516-6187
         kim@blueshirtgroup.com

(MEIL) Announces Proposed Public Offering of Common Stock

(NEON) Announces Closing of $10 Million Private Placement

SANTA CLARA, Calif., May 19, 2014  — Neonode Inc. (Nasdaq:NEON), the optical touch technology company, announced today the closing of a previously-announced private placement of common stock for $10 million in gross proceeds.

Under the terms of the private placement, Neonode issued to an institutional investor 2,500,000 shares of common stock at a price of $4.00 per share and a warrant to purchase an additional 2,500,000 shares of common stock at an exercise price of $5.09. The warrant is exercisable for 18 months. If the warrant for 2,500,000 shares of common stock at an exercise price of $5.09 is fully exercised for cash, Neonode will receive an additional $12.7 million in gross proceeds.

The securities offered in the private placement described in this press release have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act of 1933 and such applicable state securities laws.

This press release does not and shall not constitute an offer to sell, or a solicitation of an offer to buy, the securities, nor shall there be any offer, solicitation, or sale of the securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Neonode

Neonode Inc. (Nasdaq:NEON) develops and licenses the next generation of Multisensing touch technologies, allowing companies to differentiate themselves by making high performing touch solutions at a competitive cost. Neonode is at the forefront of providing unparalleled user experiences that offer significant advantages for OEM’s. This includes state-of-the-art touch technology features such as low latency pen or brush sensing, remarkably high speed scanning, proximity-, pressure-, and depth-sensing capabilities and object-size measuring.

Neonode’s patented Multisensing technology is developed for a wide range of devices such as mobile phones, tablets and e-readers, toys and gaming consoles, printers, white goods, wearable goods and advanced automotive infotainment systems. Neonode, the Neonode logo, Multisensing, and zForce are trademarks of Neonode Inc. registered in the United States and other countries. Liquid Sensing, It Makes Sense and AlwaysON are trademarks of Neonode Inc. For more information please visit www.neonode.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include, but are not limited to, statements relating to expectations, future performance or future events, and product cost, performance, and functionality matters. These statements are based on current assumptions, expectations and information available to Neonode management and involve a number of known and unknown risks, uncertainties and other factors that may cause Neonode’s actual results, levels of activity, performance or achievements to be materially different from any expressed or implied by these forward-looking statements.

These risks, uncertainties, and factors are discussed under “Risk Factors” and elsewhere in Neonode’s public filings with the Securities and Exchange Commission from time to time, including Neonode’s most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. You are advised to carefully consider these various risks, uncertainties and other factors. Although Neonode management believes that the forward-looking statements contained in this press release are reasonable, it can give no assurance that its expectations will be fulfilled. Forward-looking statements are made as of today’s date, and Neonode undertakes no duty to update or revise them.

© 2014, Neonode Inc. All rights reserved. Neonode is a registered trademark of Neonode Inc.

CONTACT: Investor Relations:
         Daniel Gelbtuch
         P: +1 917.509.9582
         Email: daniel.gelbtuch@neonode.com

(HILL) Patented Storage Innovations Make Storage Smarter, Improve Ease-of-Use

Four New Patents Make it Easier for Organizations to Add Storage Capacity, Protect Enterprise Data and Reduce Power Costs

LONGMONT, Colo., May 19, 2014  — Dot Hill Systems Corp. (Nasdaq:HILL), a trusted supplier of innovative enterprise-class storage systems, today announced four new additions to its extensive patent portfolio that describe innovations that make it easier for organizations to increase storage capacity, safeguard data assets and reduce power costs.

Writing distinct data to snapshot clones

Inventions described in Dot Hill’s 93^rd US patent, numbered 8,656,123, preserves snapshots during data cloning. Snapshots provide a versatile feature that is useful for backup and data recovery. However, traditional snapshots are read-only accessible and their contents cannot be modified, which limits their usability. A relatively recent advance in backup facilities is the ability to “clone” an existing snapshot, and perform a backup of the clone instead of the active file system. Clones, however, have the same read-only restrictions imposed on them as their parent snapshots and those that do not have read-only restrictions cannot be counted on to represent the actual point-in-time that the snapshot was taken. Dot Hill’s innovation provides a clone snapshot with a unique, separate write area. This allows host computers and applications to write unique data to the clone snapshot, separate from any other snapshot or the storage volume. Additionally, multiple concurrent clone snapshots may be created and maintained by the storage controller. This allows independent testing and evaluation to be conducted without altering either the storage volume or the regular (non-clone) snapshots.

Adding storage capacity without powering down the system

Unlike previous methods that take storage devices offline while a RAID array is being expanded, Dot Hill’s 94th US patent, numbered 8,656,131, describes technology that allows full read and write access to the array during the addition of a JBOD expansion chassis. Dot Hill’s innovation also allows immediate access to the new capacity before the array data has been reordered. The invention can be used for multiple RAID arrays including both parity and non-parity arrays. The memory required for temporary data storage during the reconfiguration operation may be provided either in the storage controller itself or in free space in any connected storage device.

Protecting data at reduced cost during power outages

The inventions in Dot Hill’s 95th US patent, numbered 8,694,812, allows lower-powered backups using small super-capacitors, in the event of a power outage. When main power is lost, Dot Hill controllers move data and metadata in the storage controller volatile memory to onboard non-volatile memory. Backup power must be provided to the volatile memory, the memory controller, and the non-volatile memory during the backup process. Once moved to the non-volatile memory, the backup power is shut down until main power is restored. The data and metadata are safe in non-volatile memory and can remain there indefinitely. Dot Hill’s innovation saves power by moving the data and metadata in stages between volatile and non-volatile memory, and putting the volatile memory into a low-power self-refresh mode while the slower non-volatile memory is storing the data and metadata. This reduces the power required to move all of the data and metadata from the volatile memory, which means a smaller or less expensive backup power source may be used, compared to conventional approaches.

Simplifying the addition and removal of drives

In the past, storage device modules have required levers and other mechanical devices, which add complexity and cost to storage arrays. Dot Hill’s world-class engineers have removed many of these unnecessary components with innovations described in the company’s 96^th US Patent #8,717,753, resulting in a simpler design with fewer parts that weighs less and saves space and costs. Now storage device modules can be inserted with a simple push of the hand. To remove the module from the chassis, a user simply slides a finger lever horizontally across the front. An ejection spring gently ejects the storage device, allowing a user to safely and easily remove modules from the storage chassis. This compact design eliminates bulky bezels and the need for additional space requirements.

“Our extensive patent portfolio and the real-world innovations that we implement to solve users’ daily storage challenges are a result of Dot Hill’s world-class engineering team,” said Ken Day, chief technology officer, Dot Hill. “In addition to 99.999 percent data availability, we are perpetually devising ways to make AssuredSAN storage solutions easier and more practical than competitive offerings.”

Dot Hill’s patent portfolio builds on the extensive intellectual property behind Dot Hill AssuredSAN and AssuredSAN Pro solutions, which deliver rock-solid, wicked-fast solutions to customers and OEM partners. As well, continuous innovation benefits Dot Hill’s key vertical market customers in the Media & Entertainment, Telecommunications, Oil & Gas, Big Data & Analytics and Digital Imaging sectors, that require high-performing storage to support demanding applications.

About Dot Hill

Leveraging its proprietary Assured family of storage solutions, Dot Hill solves many of today’s most challenging storage problems – helping IT to improve performance, increase availability, simplify operations, and reduce costs. Dot Hill’s solutions combine breakthrough software with the industry’s most flexible and extensive hardware platform and automated management to deliver best-in-class solutions. Headquartered in Longmont, Colo., Dot Hill has offices and/or representatives in China, Germany, India, Japan, Singapore, the United Kingdom, and the United States.

For more information, visit us at www.dothill.com.

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. For a discussion of such risks and uncertainties that Dot Hill may face, please consult the Company’s most recent Forms 10-Q and 10-K filed with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and Dot Hill undertakes no obligation to update such statements to reflect events that occur or circumstances that occur afterward.

HILL-G

CONTACT: Steve Sturgeon 
         Lutz PR (for Dot Hill Systems)
         858-472-5669
         steve@lutzpr.com

         Company Contact:
         Ruth Macdonald
         Dot Hill Systems
         303-845-3364
         ruth.macdonald@dothill.com

(NBS) Expands Patent Portfolio With Grant of Two European Patents

NEW YORK, May 19, 2014  — NeoStem, Inc. (Nasdaq:NBS) (“NeoStem” or the “Company”), a leader in the emerging cellular therapy industry, today announced the expansion of its intellectual property protection surrounding its CD34 Cell Program in which it is developing therapeutics to address ischemia, the process that occurs when the supply of oxygenated blood in the body is restricted. AMR-001 is the Company’s most clinically advanced product candidate in its CD34 Cell Program and is being developed to treat damaged heat muscle following a heart attack.

The European Patent Office has notified the Company that it has granted patent numbers 1951864 and 2441461 for “Compositions and Methods of Vascular Injury Repair.” These represent NeoStem’s first granted European patents for its CD34 Cell Program and bring the Program’s total worldwide patent coverage to 16 granted and allowed patents.

“We are pleased to be building our international patent portfolio in the European Union and other geographic locations,” said Dr. Robin L. Smith, Chairman and CEO of NeoStem. “We hope that laying this foundation now will support partnering activities once data from our Phase 2 PreSERVE clinical trial for AMR-001 becomes available later this year.”

The continued expansion of the Company’s intellectual property portfolio both domestically and internationally expands the commercial possibilities for its CD34 Cell Program, should any of these products in development receive regulatory approval. In the past year, NeoStem has announced expansion of its patent protection for its CD34 Cell Program in the U.S. and around the globe, including Japan, Canada, Russia, Malaysia, the Philippines, and now the European Union.

Heart attacks and cardiovascular disease are significant threats to public health in many countries, not just the U.S. If approved by the FDA and other worldwide regulatory agencies, AMR-001 could address significant unmet medical needs in the treatment of cardiovascular disease around the world.

It is estimated that each year cardiovascular disease causes over 1.9 million deaths in the European Union and costs its economy almost $270 billion. It has further been estimated that in Europe, 6.5 million patients suffer from chronic heart failure and this number is rising due to the aging of the population. A study published in The European Heart Journal (2010) found that the annual incidence of hospital admission for any AMI varied between 90–312 per 100,000 per year, with the incidence of ST segment elevation myocardial infarction (“STEMI”) alone ranging from 44 to 142 per 100,000.

NeoStem announced completion of enrollment in its Phase 2 PreSERVE AMI clinical trial in Q4 2013, a randomized, double-blind placebo-controlled study testing AMR-001for the treatment of patients with left ventricular dysfunction following STEMI. Data read out is expected in 2H 2014 and the Company expects to advance the technology into other clinical indications, such as chronic heart failure, traumatic brain injury and/or critical limb ischemia.

About NeoStem’s CD34 Cell Program

NeoStem is developing therapies to address ischemia through its CD34 Cell Program. Ischemia occurs when the supply of oxygenated blood in the body is restricted. The Company’s therapeutics seek to reverse this restriction through the development and formation of new blood vessels. The Program’s lead product candidate is AMR-001, a chemotactic hematopoietic stem cell product comprised of autologous bone marrow derived CD34/CXCR4 cells selected to treat damaged heart muscle following AMI (heart attack). AMR-001 works by increasing microvascular blood flow in the heart muscle via the development and formation of new blood vessels, thereby reversing the restriction of blood supply caused by a heart attack and rescuing tissue from eventual cell death.

About NeoStem

NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy, the Company’s ability to develop and grow its business, the successful development of cellular therapies with respect to the Company’s research and development and clinical evaluation efforts in connection with the Company’s Targeted Immunotherapy Program, CD34 Cell Program (including whether or not the Company’s Phase 2 PreSERVE clinical trial will generate positive data), T Regulatory Cell Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the performance and planned expansion of the Company’s contract development and manufacturing business. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 13, 2014, the Company’s Current Report on Form 8-K filed with the SEC on May 8, 2014 and in the Company’s other periodic filings with the SEC. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: Investor Contact:
         LifeSci Advisors, LLC
         Michael Rice
         Founding Partner
         Phone: +1-646-597-6979
         Email: mrice@lifesciadvisors.com

         Media Contact:
         NeoStem, Inc.
         Eric Powers
         Manager of Communications and Marketing
         Phone: +1-212-584-4173
         Email: epowers@neostem.com

(INFN) & DANTE Win Global Telecoms Business Innovation Award

(IMI) SanDisk and Toshiba Exclusive License to Memory Tech IP

SAN JOSE, Calif., May 19, 2014  — Intermolecular, Inc. (Nasdaq:IMI)—accelerating research and development for semiconductor and clean energy industries— today announced that SanDisk and Toshiba have jointly elected to take an exclusive license, in a limited field, to Intermolecular’s rights in the intellectual property developed under the collaborative development program (CDP) and Intermolecular’s background intellectual property thereto. The related technologies have been developed for next-generation memory. The companies’ CDP with Intermolecular, specifically aimed at developing certain memory products, materials, processes and device technologies, was concluded on March 15, 2014. Under the terms of the exclusive license, SanDisk and Toshiba will prepay non-refundable royalties in quarterly installments over a predetermined period.

“We believe the memory technology developed within this Collaborative Development Program will result in a competitive advantage for SanDisk and Toshiba in the semiconductor memory market,” stated David Lazovsky, President and CEO of Intermolecular. “The IP that has been licensed by these customers is the direct result of leveraging Intermolecular’s High Productivity Combinatorial (HPC™) technology platform to accelerate research and development. Beyond delivering value to our customers, this license further validates our unique business model for co-developing and licensing differentiated materials, process and device IP to leading integrated device manufacturers.”

About Intermolecular, Inc.

Intermolecular^® has pioneered a proprietary approach to accelerate research and development, innovation, and time-to-market for the semiconductor and clean energy industries. The approach consists of its proprietary High Productivity Combinatorial (HPC™) platform, application-specific workflows and its multi-disciplinary team.  Through paid collaborative development programs (CDPs) with its customers, Intermolecular develops proprietary technology and intellectual property for its customers focused on advanced materials, processes, integration and device architectures.  Founded in 2004, Intermolecular is based in San Jose, California.  “Intermolecular” and the Intermolecular logo are registered trademarks; and “HPC” is a trademark of Intermolecular, Inc.; all rights reserved.  Learn more at www.intermolecular.com.

CONTACT: Press Contact
         David Moreno
         MCA Public Relations
         dmoreno@mcapr.com
         +1.650.968.8900 x125

         Investors
         Rick Neely
         Intermolecular
         Sr. Vice President and Chief Financial Officer
         rick.neely@intermolecular.com
         +1.408.582.5430

(NEWL) Announces Delivery of One Eco-Type Handysize Vessel

PIRAEUS, Greece, May 19, 2014  — NewLead Holdings Ltd. (NASDAQ: NEWL) (“NewLead” or the “Company”) announced today that the “Newlead Albion”, a 2012-built dry-bulk eco-type Handysize vessel of 32,318 dwt, was delivered to NewLead’s fleet on Monday, May 19, 2014.

The Newlead Albion is trading on the spot market and is expected to generate $2.0 million EBITDA per year assuming $1.73 million yearly OPEX.

The Newlead Albion is one of the two eco-type vessels that the Company agreed to acquire in March 2014, as previously announced, for a total acquisition price of $37.0 million, $18.5 million each. Today, the market value of these vessels is estimated to be approximately $20.25 million each. The second vessel is expected to be delivered to NewLead’s fleet, as scheduled, in July 2014.

The Company financed the Newlead Albion through a combination of cash and external financing. Specifically, in March 2014, the Company paid a deposit of $1.85 million in cash, and the remaining balance was paid through the combination of cash and 75% financing in a transaction arranged by Pareto Project Finance AS and supported by strong institutional investors.

Mr. Michael Zolotas, Chairman and Chief Executive Officer of NewLead, stated, “We are pleased to announce the delivery of the Newlead Albion, the first vessel to be added to our fleet after our successful restructuring. To receive delivery, we secured financing through a leading shipping and financial institution, demonstrating third party belief in the transformation of NewLead.”

Michael Zolotas, added, “We are modernizing our fleet with fuel efficient vessels. The fleet age is being optimized, and employment lifetime is substantially longer. NewLead expects to have three new modern Handysize vessels added to its fleet by the end of August 2014.”

About NewLead Holdings Ltd.
NewLead Holdings Ltd. is an international, vertically integrated shipping, logistics and commodity company. NewLead owns two dry bulk Panamax vessels and manages three third party tanker vessels, two small bitumen tanker vessels and one Handysize MR product tanker. The Company expects to take delivery of three modern eco-type dry bulk Handysize vessels, one of which is newbuilding, between May and August 2014. The Company has also signed a term sheet for 75% financing to acquire two dry bulk Panamax vessels. Upon completion of the above acquisitions and together with the vessels under management. NewLead is expected to have a fleet of ten vessels, seven owned and three vessels under management. Furthermore, the Company owns a wash plant and a mine in Kentucky, USA and has been granted access to develop and mine another mine, that includes a CSX rail load facility, the Andy Rail Terminal, in Kentucky, USA. NewLead’s common shares are traded under the symbol “NEWL” on the NASDAQ Global Select Market. To learn more about NewLead Holdings Ltd., please visit the new website at www.newleadholdings.com.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995
This press release includes assumptions, expectations, projections, intentions and beliefs about future events. These statements, as well as words such as “anticipate,” “estimate,” “project,” “plan,” and “expect,” are intended to be ”forward-looking” statements. We caution that assumptions, expectations, projections, intentions and beliefs about future events may vary from actual results and the differences can be material. Forward-looking statements include, but are not limited to, such matters as the creditworthiness of our counterparties, the reliability of reserve reports, our ability to extract or acquire coal to fulfill contracts, the consummation of conditional contracts, future operating or financial results; our liquidity position and cash flows, our ability to borrow additional amounts under our revolving credit facility and, if needed, to obtain waivers from our lenders and restructure our debt, and our ability to continue as a going concern; statements about planned, pending or recent vessel disposals and/or acquisitions, business strategy, future dividend payments and expected capital spending or operating expenses, including dry-docking and insurance costs; statements about trends in the product tanker and dry bulk vessel shipping segments, including charter rates and factors affecting supply and demand; expectations regarding the availability of vessel acquisitions; completion of repairs; length of off-hire; availability of charters; and anticipated developments with respect to any pending litigation. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although NewLead believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, NewLead cannot assure you that it will achieve or accomplish these expectations, beliefs or projections described in the forward looking statements. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include the strength of world economies and currencies, general market conditions, including changes in charter rates and vessel values, failure of a seller to deliver one or more vessels, and other factors discussed in NewLead’s filings with the U.S. Securities and Exchange Commission from time to time. NewLead expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in NewLead’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Investor and Media Relations:
Elisa Gerouki
NewLead Holdings Ltd.
Telephone: + 30 213 014 8023
Email: egerouki@newleadholdings.com

(RDI) Announces Stock Buy-back Program

Reading International, Inc. (NASDAQ:RDI) announced today that the company’s board of directors has authorized management, at its discretion, to spend from time to time up to an aggregate of $10,000,000 to acquire shares of Reading’s Common Stock.

This approved stock repurchase plan will supercede and effectively cancel the existing program that was approved by the board on May 14, 2004 which allowed management to purchase up to 350,000 shares of Reading’s Common Stock. Under this plan 245,675 shares have been repurchased, as of today’s date.

The repurchase program will allow Reading to repurchase its shares from time to time in accordance with the requirements of the Securities and Exchange Commission on the open market, in block trades and in privately negotiated transactions, depending on market conditions and other factors. All purchases are subject to the availability of shares at prices that are acceptable to Reading, and accordingly, no assurances can be given as to the timing or number of shares that may ultimately be acquired pursuant to this authorization.

Reading is currently active in the open market buying back its shares.

About Reading International, Inc.

Reading International (http://www.readingrdi.com) is in the business of owning and operating cinemas and developing, owning and operating real estate assets. Our business consists primarily of:

• the development, ownership and operation of multiplex cinemas in the United States, Australia and New Zealand; and
• the development, ownership, and operation of retail and commercial real estate in Australia, New Zealand, and the United States, including entertainment-themed retail centers (“ETRC”) in Australia and New Zealand and live theater assets in Manhattan and Chicago in the United States.

Reading manages its worldwide business under various different brands:

• in the United States, under the
  • Reading brand (http://www.readingcinemasus.com);
  • Angelika Film Center brand (http://www.angelikafilmcenter.com);
  • Consolidated Theatres brand (http://www.consolidatedtheatres.com);
  • City Cinemas brand (http://www.citycinemas.com);
  • Beekman Theatre brand (http://www.beekmantheatre.com);
  • The Paris Theatre brand (http://www.theparistheatre.com);
  • Liberty Theatres brand (http://libertytheatresusa.com/); and
  • Village East Cinema brand (http://villageeastcinema.com)
• in Australia, under the
  • Reading brand (http://www.readingcinemas.com.au); and
  • Newmarket brand (http://readingnewmarket.com.au)
• in New Zealand, under the
  • Reading brand (http://www.readingcinemas.co.nz);
  • Rialto brand (http://www.rialto.co.nz);
  • Reading Properties brand (http://readingproperties.co.nz);
  • Courtenay Central brand (http://www.readingcourtenay.co.nz);
  • Steer n’ Beer restaurant brand (http://steernbeer.co.nz); and
  • Taupo Motel brand (http://www.sailstaupo.co.nz).

(LIOX) Announces Acquisition Of Digital Marketing Agency, Darwin Zone

Costa Rica-Based Firm Adds Near-Shore Scale and Expertise to Support Lionbridge’s Rapidly-growing Global Digital Marketing Offerings

WALTHAM, Mass., May 16, 2014  — Lionbridge Technologies, Inc. (Nasdaq: LIOX) today announced that it has acquired Darwin Zone, a full-service Digital Marketing Services agency based in Costa Rica. Darwin Zone’s 70 highly-skilled professionals in digital marketing campaign management, social media, search engine marketing and analytics, enable Lionbridge to add near-shore operations and expertise to support its growing digital marketing services offerings.

“Our digital marketing offerings are a cornerstone of our growth strategy. Global marketers across industries now rely on our proven crowd-in-the-cloud solutions to manage the complexity of real time, digital content, across geographies, platforms and languages,” said Rory Cowan, CEO of Lionbridge.  “Darwin’s ideal combination of skill, geography and cost complements our global capabilities and provides high quality digital marketing services in the time zone of our clients’ US marketing teams. This addition also bolsters our presence in Latin America and allows us to efficiently scale our business to meet our clients’ evolving digital content needs.”

Darwin is an integrated digital agency that enables marketers and advertisers to more effectively create, manage and grow high-impact digital marketing campaigns. Darwin integrates world-class solutions to help marketing organizations run holistic campaigns across multiple channels. The company provides services for several long-standing clients including many brand leaders in the Latin America region.

Lionbridge is acquiring Darwin Zone for a total estimated cash consideration of approximately $2.4 million. The Company expects the acquisition to be neutral to earnings in 2014, including minimal acquisition and integration costs.

About Lionbridge
Lionbridge enables more than 800 world-leading brands to increase international market share, speed adoption of products and effectively engage their customers in local markets worldwide. Using our proprietary cloud technology platforms and our global crowd of more than 100,000 professionals we provide translation, online marketing, content management and application testing solutions that ensure global consistency and local relevance across all touch points of the customer lifecycle. Based in Waltham, Mass., Lionbridge maintains solution centers in 26 countries. To learn more, visit http://www.lionbridge.com.

Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including expectations for accretion, revenue and earnings related to the acquisition of Darwin Zone in 2014. Lionbridge’s actual experiences, actions, financial and operating results may differ materially from those discussed in the forward-looking statements. Factors that might cause such a difference include the termination of customer contracts prior to the end of their term; integration expense; delays in integration; employee retention following acquisition; the loss of a major client or customer costs associated with and consequential to the acquisition and integration of Darwin and benefits realized from the acquisition risks associated with management of growth, transition and integration; the failure to keep pace with the rapidly changing requirements of its clients; Lionbridge’s ability to attract and retain key personnel; risks associated with competition and competitive pricing pressures; and Lionbridge’s ability to forecast revenue and operating results. For a more detailed description of the risk factors associated with Lionbridge, please refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 and subsequent filings with the SEC (copies of which may be accessed through the SEC’s website at http://www.sec.gov.

CONTACT: Sara Buda, Lionbridge, 781-434-6190, sara.buda@lionbridge.com

(OXGN) Names Experienced Biotech Executive, David J. Chaplin, Ph.D., President & CEO

SOUTH SAN FRANCISCO, Calif., May 16, 2014  — OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that David (Dai) Chaplin, Ph.D., has been appointed to the position of President and Chief Executive Officer, replacing Peter Langecker, M.D., Ph.D.

Dr. Chaplin, a recognized international leader in pharmacology and tumor biology, and a current member of OXiGENE’s Board of Directors, brings extensive experience in the fields of oncology research and cancer drug development. Dr. Chaplin has served as a senior member of the management team of several biopharma companies. During this time, his pioneering research and development in the area of vascular disrupting strategies resulted in the identification of Combretastatin A4P (ZYBRESTAT®) (fosbretabulin tromethamine), a promising anti-cancer therapy currently in advanced clinical trials. Prior to joining OXiGENE in 2000 as Chief Scientific Officer, Dr. Chaplin served as Vice President of Oncology for Aventis (now Sanofi), where he was in charge of all oncology drug discovery and early clinical development worldwide. He has published over 180 research papers in peer-reviewed journals, many on the subject of vascular targeting and tumor blood flow.

On behalf of OXiGENE’s board, chairman Fred Driscoll said, “We are pleased to have a person of Dai’s caliber and reputation on our management team to lead the Company and its compounds towards potential commercialization.” Mr. Driscoll continued, “Dai’s background in anti-cancer drug development, in particular his extensive knowledge of ZYBRESTAT, and his involvement with OXiGENE dating back to 2000 make him a superb choice to lead the Company at this time.”

Dr. Chaplin holds a Ph.D. in Tumor Biology from the University of London. He received a B.Sc. Honors degree in Chemistry from the University of Essex, and an M.Sc. in Pharmacology from the University of Southampton.

“I am honored to assume my new role and to lead OXiGENE in its next phase of development and growth, including the clinical, regulatory and business development activities that will be required to bring ZYBRESTAT to potential market commercialization,” commented Dr. Chaplin. “I look forward to working with the team of employees at OXiGENE as we strive to bring new therapeutics to patients with significant unmet medical needs.”

Mr. Driscoll concluded, “We thank Peter Langecker for his leadership over the past five years during an important and challenging phase of OXiGENE’s growth and development. We wish Peter success in his future endeavors.”

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer. The Company is focused on developing vascular disrupting agents (VDAs), which are compounds that selectively disrupt abnormal blood vessels associated with solid tumor survival and progression. The Company’s lead clinical product candidate, ZYBRESTAT^® (fosbretabulin tromethamine), is in development as a potential treatment for solid tumors. OXi4503, its second-generation product candidate, is in development for acute myeloid leukemia (AML). OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

Safe Harbor Statement

This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include the timing of advancement, outcomes, data and regulatory guidance relative to our clinical programs and achievement of our business and financing objectives may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the inherent risks of drug development, manufacturing and regulatory review, and the availability of additional financing to continue development of our programs. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE’s reports to the Securities and Exchange Commission, including OXiGENE’s reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2013.

CONTACT: Investor and Media Contact:
         ir@oxigene.com
         650-635-7000

(NEPT) Announces Proposed Director Nominees for Its Upcoming Annual General Meeting

LAVAL, Quebec, May 16, 2014  — Neptune Technologies & Bioressources Inc. (“Neptune” or the “Corporation”) (Nasdaq:NEPT) (TSX:NTB), announced today that the Corporation will nominate as management’s director nominees for the upcoming annual general meeting of Neptune shareholders, the following eight individuals:

The proposed nominations follow an agreement between Neptune and Mr. George Haywood, the largest shareholder of Neptune, who have agreed to work together in the best interests of all stakeholders of Neptune.

Dr. Denis, Mr. Boivin, Dr. Waksal and Dr. Tuckson are current members of Neptune’s board of directors. As previously announced, Mr. Wenker and Mr. Moretz were appointed as a special advisors to the board December 19, 2013 and February 18, 2014 respectively.

Details on each of the new proposed management director nominees are set forth below:

Mr. Fitzgibbon is the President and Chief Executive Officer of Atrium Innovations Inc., a leader in the development, manufacturing and marketing of added value products for the health and nutrition industry, which was recently sold to corporations backed by the Permira funds in a transaction valued at over $1.1 billion. Prior to joining Atrium Innovations, Mr. Fitzgibbon was Vice-Chairman of National Bank Financial and Senior Vice-President, Finance, Technology and Corporate Affairs at National Bank of Canada. He holds a bachelor’s degree in business administration from the École des hautes études commerciales of Montreal and a certificate in general management from Harvard Business School. Mr. Fitzgibbon currently serves on the board of directors of other corporations.

Mr. Montgomery is the Chief Investment Officer of Tuckamore Capital, a publicly-traded company that has invested approximately $700 million in successful private businesses since its inception in 2005. Prior to joining Tuckamore, he headed business development at Rogers Media Inc. Mr. Montgomery is a lawyer and member of the New York State Bar and currently serves on the boards of Epsilon Energy, a TSX-listed Company, and the Toronto East General Hospital Foundation.

Neptune continues its search process for a new CEO and plans to retain a top-tier executive search firm to assist it in the process.

About Neptune Technologies & Bioressources Inc.

Neptune is a biotechnology company engaged primarily in the development and commercialization of marine-derived omega-3 polyunsaturated fatty acids (”PUFAs”). Neptune has a patented process of extracting oils from Antarctic krill, and principally sells omega-3 PUFAs as bulk oil to Neptune’s distributors who commercialize them under their private label primarily in the U.S., European and Australian nutraceutical markets. Neptune’s products generally come in bulk oil or capsule form and serve as a dietary supplement to consumers. Neptune’s head office is located at 545 Promenade du Centropolis, Suite 100, Laval, Quebec.

Neptune holds approximately 49% of the participating and voting rights of Acasti Pharma Inc. (“Acasti“) and 96% of the voting rights of NeuroBioPharm Inc. (“NeuroBio“). Through these subsidiaries, Neptune is also pursuing opportunities in the medical food and prescription drug markets. Acasti and NeuroBioPharm respectively focus on the research and development of safe and therapeutically effective compounds for highly prevalent atherosclerotic conditions, such as cardiometabolic disorders and cardiovascular diseases, and for neurodegenerative and inflammation related conditions. Acasti’s lead prescription drug candidate is CaPre^®, a purified high omega-3 phospholipid concentrate derived from Neptune krill oil being developed to address the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia, which is characterized by abnormally high levels of triglycerides.

Forward-Looking Statements

Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements” within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Neptune to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “will,” or “plans” to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

The forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement and the “Cautionary Note Regarding Forward-Looking Statements” section contained in Neptune’s latest prospectus supplement, available on SEDAR at www.sedar.com (the “Prospectus Supplement”). All forward-looking statements in this press release are made as of the date of this press release. Neptune does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Neptune public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Additional information about these assumptions and risks and uncertainties is contained in the Prospectus Supplement under “Risk Factors.”

Neither NASDAQ nor the Toronto Stock Exchange accepts responsibility for the adequacy or accuracy of this release.

CONTACT: Neptune Contacts:
         Andre Godin
         Chief Financial Officer
         +1.450.687.2262
         a.godin@neptunebiotech.com
         neptunebiotech.com

         John Ripplinger
         Investor Relations
         +1.450.687.2262
         j.ripplinger@neptunebiotech.com
         neptunebiotech.com

(AMAT) to Present at Upcoming Investor Conferences

SANTA CLARA, Calif., May 16, 2014 – Applied Materials, Inc. announced today that Robert Halliday, Senior Vice President and CFO, will participate in a question-and-answer session at the Cowen and Company Technology, Media & Telecom Conference in New York City on Wednesday, May 28 beginning at 12:00 p.m. ET / 9:00 a.m. PT.

Mr. Halliday will also participate in a question-and-answer session at the Bank of America Merrill Lynch Global Technology Conference in San Francisco on Tuesday, June 3 beginning at 12:15 p.m. ET / 9:15 a.m. PT.

A live audio webcast of the sessions will be available on the Applied Materials website at http://www.appliedmaterials.com/company/investor-relations, and a replay will remain available for three months after the live event.

Applied Materials, Inc. (Nasdaq:AMAT) is the global leader in providing innovative equipment, services and software to enable the manufacture of advanced semiconductor, flat panel displays and solar photovoltaic products. Our technologies help make innovations like smartphones, flat screen TVs and solar panels more affordable and accessible to consumers and businesses around the world. Learn more at www.appliedmaterials.com.

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Applied Materials via Globenewswire

Contact:
Kevin Winston (editorial/media) 408.235.4498
Michael Sullivan (investment community) 408.748.5227

(TEDU) Signs Strategic Partnership Agreement With Red Hat China

BEIJING, May 16, 2014  — Tarena International, Inc. (Nasdaq:TEDU) (“Tarena” or the “Company”), a leading provider of professional education services in China, today announced that it has signed a strategic partnership agreement with Red Hat China (“Red Hat”), the world’s leading provider of open source solutions, and is now an authorized Red Hat training and certification partner in China.

Through the partnership with Red Hat, Tarena will continue to refine and optimize its Linux and network engineering course offering. Pursuant to the partnership agreement, Tarena will be able to offer Red Hat Training and Certification courses including RHCE (Red Hat Certified Engineer), RHCA (Red Hat Certified Architect) and OpenStack courses. Tarena students can sign up for Red Hat certification exams at Tarena’s learning centers upon graduation from its Linux and network engineering course.

“We endeavor to increase our efforts of training more network engineers in China,” said Shaoyun Han, Founder, CEO and Chairman of Tarena. “Through our strategic partnership with Red Hat, Tarena students can receive world class network engineering training and earn the official validation from the industry leader to help achieve their career aspirations. This is exactly the rationale behind our partnership with Red Hat.”

“Tarena is a leading professional education services provider in China with high quality IT education and respected brand in the industry,” said Changchun Liu, technical director of Red Hat Greater China. “Given Tarena’s large students enrollment, comprehensive IT course offerings and elite instructor team, we hope to further promote Linux technology in China and train more world class Linux engineers together with Tarena through our partnership.”

About Tarena International, Inc.

Tarena International, Inc. (Nasdaq:TEDU) is a leading provider of professional education services in China. The Company is the largest provider of IT professional education services in China with a market share of 8.3% as measured by revenues in 2013 according to IDC, a third-party research firm. Through its innovative education platform combining live distance instruction, classroom-based tutoring and online learning modules, Tarena offers courses in nine IT subjects and two non-IT subjects. Its courses provide students with practical education to prepare them for jobs in industries with significant growth potential and strong hiring demand. Since its inception in 2002, Tarena has trained over 130,000 students, cooperated with more than 500 universities and colleges and placed students with approximately 35,000 corporate employers in a variety of industries. For further information, please visit http://ir.tarena.com.cn.

About Red Hat, Inc.

Red Hat (NYSE:RHT) is the world’s leader of open source software solutions, using a community-powered approach to reliable and high-performing cloud, Linux, middleware, storage and virtualization technologies. Red Hat also offers award-winning support, training, and consulting services. As the connective hub in a global network of enterprises, partners, and open source communities, Red Hat helps create relevant, innovative technologies that liberate resources for growth and prepare customers for the future of IT. Learn more at http://www.redhat.com.

CONTACT: For investor and media inquiries, please contact:
         Tarena International, Inc.
         Christina Zhu
         Tel: +86-10-5621 9451
         Email: zhumy@tarena.com.cn

(NBS) Subsidiary, Progenitor Cell Therapy, Awarded FACT Re-Accreditation

NEW YORK, May 15, 2014  — NeoStem, Inc. (Nasdaq:NBS) (“NeoStem” or the “Company”), a leader in the emerging cellular therapy industry, and its subsidiary, Progenitor Cell Therapy, LLC (“PCT”), announced today that PCT has been awarded re-accreditation by the Foundation for the Accreditation of Cellular Therapy (FACT). By demonstrating compliance with the FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing and Administration, PCT has earned FACT Accreditation for its Allendale, New Jersey and Mountain View, California sites. PCT’s accreditation is effective for three years beginning October 19, 2013.

“We are proud, once again, to obtain accreditation by FACT. We understand that our clients put a great deal of trust in PCT to deliver high quality products and consistent results, and the FACT accreditation is just one of the many ways that we demonstrate that our programs consistently meet or exceed industry standards for the use of cellular products,” said Dr. Robert Preti, Chief Scientific Officer of NeoStem and PCT and President of PCT.

FACT is an internationally-recognized accrediting body for hospitals and medical institutions offering stem cell transplant, and indicates the accredited institution has met the most rigorous standards in every aspect of stem cell therapy. This covers the entire spectrum of stem cell therapy, from clinical care to donor management, cell collection, processing, storage, transportation, administration, and cell release. FACT-JACIE Standards are defined by leading experts based on the latest knowledge of the field of cellular therapy transplantation.

“FACT accreditation and the certification of other leading regulatory bodies demonstrate that PCT is meeting the highest standards of quality for stem cell therapy,” says Dr. Robin Smith, Chairman and CEO of NeoStem. “With more than 15 years of expertise in helping clients achieve their manufacturing and development goals, PCT has set a high bar for the cellular therapy industry.”

About PCT

Progenitor Cell Therapy (PCT), a wholly owned subsidiary of NeoStem, Inc., is a leading contract development and manufacturing organization in the cellular therapy industry. For over 15 years, PCT has provided pre-clinical and clinical cGMP development and manufacturing services to more than 100 clients, advancing regenerative medicine product candidates from the development stage all the way through to human testing. PCT has two cGMP-compliant, state-of-the art facilities in New Jersey and California to serve the cell therapy industry and offers manufacturing of cell therapy-based products, engineering and innovation services, process and product development, cell and tissue processing, collection and storage, regulatory consulting, facility design, validation, and due diligence evaluations. www.pctcelltherapy.com

About NeoStem, Inc.

NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com

About FACT

In December 1994, the International Society for Cellular Therapy (ISCT) and the American Society for Blood and Marrow Transplantation (ASBMT) merged their Standards into a single document covering all aspects of hematopoietic cell therapy (collection, processing, and transplantation). The two societies established FACT in order to develop a voluntary Inspection and Accreditation Program based on the joint Standards.  FACT promotes quality medical and laboratory practice of cellular therapy through its peer-developed standards and voluntary inspection and accreditation program.

In 2006, FACT, in collaboration with the Joint Accreditation Committee–ISCT & EBMT (JACIE), developed international standards in the field of cellular therapy. JACIE was founded by the European Group for Blood and Marrow Transplantation (EBMT) and the International Society for Cellular Therapy (ISCT), the two leading scientific organizations involved with cellular transplantation in Europe.

Since 2007, FACT accreditation has been used in determining the U.S. News & World Report rankings of transplant centers for the “America’s Best Hospitals” and “America’s Best Children’s Hospitals” list.

The FACT Inspection and Accreditation Program was developed by Dr. Phyllis Warkentin, Chief Medical Officer of FACT, the FACT Board of Directors, as well as the ISCT and ASBMT Regulatory and Standards Committees. The first edition of the FACT Standards was published in September 1996, and the first inspections began in September of 1997 resulting in the first program being awarded accreditation in 1998.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy, including with respect to the Company’s ability to develop and grow its business, the successful development of cellular therapies with respect to the Company’s research and development and clinical evaluation efforts in connection with the Company’s Targeted Immunotherapy Program, CD34 Cell Program and T Regulatory Cell Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the performance and planned expansion of the Company’s contract development and manufacturing business. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 13, 2014, the Company’s Current Report on Form 8-K filed with the SEC on May 8, 2014 and in the Company’s other periodic filings with the SEC. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: Investor Contact:
         LifeSci Advisors, LLC
         Michael Rice
         Founding Partner
         Phone: +1-646-597-6979
         Email: mrice@lifesciadvisors.com

         Media Contact:
         NeoStem, Inc.
         Eric Powers
         Manager of Communications and Marketing
         Phone: +1-212-584-4173
         Email: epowers@neostem.com

(HART) to Present at East Coast IDEAS Investor Conference

Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, announces that David Green, Chief Executive Officer, will present at the 2014 East Coast IDEAS Investor Conference at the Metro Meeting Center in Boston, MA. Mr. Green is scheduled to present on Thursday, June 5 at 3:50 pm in Presenting Room 1.

Mr. Green will provide an overview of the company, recent business developments and growth strategy.

The presentation will be webcast and available at the following link: http://www.wsw.com/webcast/threepa13/hart.

IDEAS Investor Conferences are sponsored by and directly for the benefit of regional investment communities. Attendees include mutual fund managers, hedge fund managers, family offices, high-net-worth investors and other accredited investors. For more information, please visit http://www.threepartadvisors.com/#!east-coast-ideas/crux.

About Harvard Apparatus Regenerative Technology

Harvard Apparatus Regenerative Technology makes regenerated organs for transplant. Our first product, the HART-Trachea, is intended to replace or repair a trachea that has been severely damaged by either trachea cancer or physical trauma. Our technology has been used in eight human trachea transplants to date approved under compassionate use exemptions, but none of our products are yet approved by a government regulatory authority for marketing. On November 1, 2013, HART was spun-off from Harvard Bioscience. The trademark “Harvard Apparatus” is used under a sublicense agreement with Harvard Bioscience, who has licensed the right to use such trademark from Harvard University.

Forward-Looking Statements

Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements include statements relating to, among other things, the planned commercialization efforts and marketing approvals of HART’s products as well as the success thereof and the availability of a market for the HART securities. These statements involve risks and uncertainties, including among other things, market conditions that may cause results to differ materially from the statements set forth in this press release. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Apparatus Regenerative Technology expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

(CSCO) & WIRED Enlist Industry Heavyweights for Tablet Publication

With Contributions From Don Tapscott, Anthony D. Williams, and Padmasree Warrior, Along With Michael Copeland of Andreessen Horowitz Cisco Debuts First User-Directed Ad Experience Available for Free Download TODAY in the WIRED iOS Storefront

(XXII) Appoints General Counsel

22nd Century Group, Inc. (NYSE MKT:XXII) today announced the appointment of Thomas L. James, Esq. as Vice President, General Counsel and Secretary, effective May 12, 2014.

“Tom possesses tremendous legal and business knowledge and experience and will be a great asset to our Company,” stated Joseph Pandolfino, Founder and Chief Executive Officer of 22nd Century Group. “He has an impressive history of achievement and has been a strong leader throughout his almost 30-year legal career. Tom has served as our outside legal and business counsel for the past decade and I am delighted to have him join our management team.”

Mr. James has served over the past 13 years as a Partner and later as an Of Counsel attorney with Foley & Lardner LLP. Prior to that time, Mr. James was an attorney with other law firms. Mr. James is a graduate of the Georgetown University Law Center in Washington, D.C. (J.D., 1985) and the University of Maryland (B.S., 1980). He is a member of the District of Columbia Bar and is also admitted to practice before the United States Supreme Court.

For additional information, please visit: www.xxiicentury.com

About 22nd Century Group, Inc.

22nd Century is a plant biotechnology company whose proprietary technology allows for the levels of nicotine and other nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in the tobacco plant to be decreased or increased through genetic engineering and plant breeding. 22nd Century owns or is the exclusive licensee of 116 issued patents in 78 countries plus an additional 42 pending patent applications. Goodrich Tobacco Company, LLC and Hercules Pharmaceuticals, LLC are wholly-owned subsidiaries of 22nd Century. Goodrich Tobacco is focused on commercial tobacco products and potentially less harmful cigarettes. Hercules Pharmaceuticals is focused on X-22, a prescription smoking cessation aid in development.

Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the fiscal year ended December 31, 2013, filed on January 30, 2014, including the section entitled “Risk Factors,” and our other reports filed with the U.S. Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.